中国血液净化

›› 2005, Vol. 4 ›› Issue (1): 26-28.

• 论著 • 上一篇    下一篇

静脉注射氢氧化铁蔗糖复合物治疗肾性贫血的临床研究和安全性分析

潘健涛 　朱 波 　许元文 　钟先阳 　黄锋先 　吴培根 　余学清   

  1. 510080 广州，中山大学附属第一医院肾内科（潘健涛，许元文，黄锋先，吴培根，余学清）；妇产科（朱波）广州，海军421医院肾内科（钟先阳）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2005-01-12 发布日期:2005-01-12

  • Received:1900-01-01 Revised:1900-01-01 Online:2005-01-12 Published:2005-01-12

RichHTML

0

PDF

202

摘要：

目的 探讨静脉注射氢氧化铁蔗糖复合物（维乐福，venofer）治疗血液透析(HD)患者肾性贫血的有效性和安全性。方法 选择30例HD患者，分为氢氧化铁蔗糖复合物组和口服铁组，每组15例。氢氧化铁蔗糖复合物组：每次血液透析时静脉注射200mg氢氧化铁蔗糖复合物＋100ml生理盐水，直至完成总补铁量；口服铁组：琥珀酸亚铁200mg，每日3次，共8周。均同时使用基因重组人红细胞生成素（EPO）50μ·Kg-1·次-1皮下注射。比较2组患者贫血治疗的效果和安全性。结果 治疗后2组患者贫血均改善，氢氧化铁蔗糖复合物组血红蛋白（Hb）上升每周(4.5±2.0)g/L，8周内Hb达到靶目标（110g）占60.0%，平均每人EPO总用量45Kμ，比口服铁组少37.5%，而口服铁组Hb上升每周(1.5±0.8)g/L，8周内无1例达到靶目标，平均每例 EPO总用量72Kμ，2组比较差异有显著性 （P<0.01）。结论 静脉注射氢氧化铁蔗糖复合物可作为伴有缺铁的血液透析患者长期补铁的方式，配合 EPO治疗贫血，疗效优于口服铁，且不良反应发生率低。

关键词: 氢氧化铁蔗糖复合物, 红细胞生成素, 肾功能衰竭, 贫血

Abstract:

Objective To examine the validity and security of Fe(OH)3-sucrose-compond (Venofer) on renal anemia of hemodialysis (HD) patients. Methods Thirty HD patients were dividied into venofer group (VG) and oral iron group (OIG) randomly and there were 15 patients in each group 200mg venofer that was dissolved in 100ml of 0.9% Nacl solution were used while the patients in VG group accepted HD until reacted the total iron deficit；200mg amber acid subiron (AASI) was taken by the patients in OIG gorup three times a day and 8 weeks in total. Erythropoietine (EPO) was used at a dose of 50u/Kg/time by hypodermic in each group. The effect and security of venofer and AASI on renal anemia were observed and compared. Results The anaemia of each group was improved after treatment. Hb was inareased at a speed of (4.5±2.0)g/L every week in VG group, and 60% patients in VG group reached the target goal (110g) in 8 weeks. The mean EPO used was about 45ku in VG group, which was 37.5% lower than OIG group: The Hbin OIG group was increased at a speed of (1.5±0.8)g/L every week and nopatients reached the torget goal in 8 weeks. The mean EPO used was about 72ku. There were significant difference between the two groups (P<0.01). Conclusion Venofer that aid for EPO is better than oral iron, and the incident rate of adverse reaction is lower in curing renal anemia, therefore, it can be used for long period to HD patients which is short of iron. 

Key words: Erythropoietine, Renal failure, Anemia

中图分类号: